Showing results (211-220 of 230) with videos related to

Sort By:
Pageof 23
The Lancet. Oncology|June 20, 2020
Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trialPanagiotis A Konstantinopoulos, Su-Chun Cheng, Andrea E Wahner Hendrickson, et al.
The New England Journal of Medicine|October 9, 2016
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian CancerMansoor R Mirza, Bradley J Monk, Jørn Herrstedt, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 22, 2013
Ovarian cancer, version 2.2013Robert J Morgan, Ronald D Alvarez, Deborah K Armstrong, et al.
The Journal of Clinical Investigation|June 16, 2022
Satellite repeat RNA expression in epithelial ovarian cancer associates with a tumor-immunosuppressive phenotypeRebecca L Porter, Siyu Sun, Micayla N Flores, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 14, 2019
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian CancerAmit M Oza, Ursula A Matulonis, Angeles Alvarez Secord, et al.
Cancer Research|November 7, 2020
Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian CancerChangxin Wan, Matthew P Keany, Han Dong, et al.
Science Advances|July 12, 2024
CAR memory-like NK cells targeting the membrane proximal domain of mesothelin demonstrate promising activity in ovarian cancerMubin Tarannum, Khanhlinh Dinh, Juliana Vergara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 23, 2025
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA MutationPanagiotis A Konstantinopoulos, Jae Weon Kim, Gilles Freyer, et al.
The Lancet. Oncology|March 19, 2019
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trialPanagiotis A Konstantinopoulos, William T Barry, Michael Birrer, et al.
Molecular Cancer Research : MCR|August 30, 2019
Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian CancerElizabeth H Stover, Maria B Baco, Ofir Cohen, et al.
Pageof 23